Prognostic significance of adipocytokines in systolic heart failure patients

European Journal of Clinical Investigation

Volumn 42, Issue 10, 2012, Pages 1079-1086

  Wu, Xue Ming ^a   Lin, Yen Hung ^b   Chen, Aaron ^c   Hsu, Tse Pin ^b   Wu, Yen Wen ^b,e   Lin, Hung Ju ^b   Hsu, Ron Bin ^b   Lee, Chi Ming ^b   Wang, Shoei Shen ^b   Lo, Men Tzung ^d   Ho, Yi Lwun ^b   Chen, Ming Fong ^b  

^a TAO YUAN GENERAL HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^d NATIONAL CENTRAL UNIVERSITY   (Taiwan)

^e FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Adipocytokine; Adiponectin; Heart failure; Leptin; Resistin; Visfatin

Indexed keywords

ADIPONECTIN; LEPTIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; RESISTIN; RETINOL BINDING PROTEIN 4;

ADULT; AGED; ARTICLE; BODY MASS; CONTROLLED STUDY; FEMALE; FOLLOW UP; FUNCTIONAL STATUS; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; SYSTOLIC HEART FAILURE;

ADIPOKINES; BIOLOGICAL MARKERS; CHRONIC DISEASE; FEMALE; HEART FAILURE, SYSTOLIC; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROGNOSIS; RISK FACTORS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84866280411     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2012.02698.x     Document Type: Article

References (57)

1. Funahashi T, Nakamura T, Shimomura I, Maeda K, Kuriyama H, Takahashi M et al. Role of adipocytokines on the pathogenesis of atherosclerosis in visceral obesity. Intern Med 1999;38:202-6.
2. Paquot N, Tappy L. [Adipocytokines: link between obesity, type 2 diabetes and atherosclerosis]. Rev Med Liege 2005;60:369-73.
3. Yamauchi T. [Roles of adipocytokines in the development of atherosclerosis]. Nihon Rinsho 2007;65(Suppl 7):63-70.
4. Mahadik SR, Deo SS, Mehtalia SD. Association of adiposity, inflammation and atherosclerosis: the role of adipocytokines and CRP in Asian Indian subjects. Metab Syndr Relat Disord 2008;6:121-8.
5. Fargnoli JL, Sun Q, Olenczuk D, Qi L, Zhu Y, Hu FB et al. Resistin is associated with biomarkers of inflammation while total and high-molecular weight adiponectin are associated with biomarkers of inflammation, insulin resistance, and endothelial function. Eur J Endocrinol 2010;162:281-8.
6. Karbowska A, Boratynska M, Klinger M. [Resistin: a pathogenic factor or a biomarker of metabolic disorders and inflammation?]. Postepy Hig Med Dosw (Online) 2009;63:485-91.
7. Konishi K, Nakano S, Seto H, Tsuda S, Koya D. Carotid atherosclerosis mediated by visceral adiposity and adipocytokines in type 2 diabetic subjects. Diabetes Res Clin Pract 2009;85:171-8.
8. Wang LM, Wang CX, Zhang DM, Xie YY. [The relationship between the serum ET and resistin concentration and the peripheral neuropathy in type 2 diabetes]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2011;27:564-5, 7.
9. Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. Circ Res 2005;96:939-49.
10. Han SH, Quon MJ, Kim JA, Koh KK. Adiponectin and cardiovascular disease: response to therapeutic interventions. J Am Coll Cardiol 2007;49:531-8.
11. Behre CJ. Adiponectin, obesity and atherosclerosis. Scand J Clin Lab Invest 2007;67:449-58.
12. de Luis DA, Ballesteros M, Ruiz E, Munoz C, Penacho A, Iglesias P et al. [Visfatin in obese patients, relation with cardiovascular risk factors, a cross sectional study]. Med Clin (Barc) 2011;137:199-203.
13. Choi KM, Lee JS, Kim EJ, Baik SH, Seo HS, Choi DS et al. Implication of lipocalin-2 and visfatin levels in patients with coronary heart disease. Eur J Endocrinol 2008;158:203-7.
14. Mohapatra J, Sharma M, Acharya A, Pandya G, Chatterjee A, Balaraman R et al. Retinol-binding protein 4: a possible role in cardiovascular complications. Br J Pharmacol 2011;164:1939-48.
15. Ingelsson E, Lind L. Circulating retinol-binding protein 4 and subclinical cardiovascular disease in the elderly. Diabetes Care 2009;32:733-5.
16. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham study. N Engl J Med 1971;285:1441-6.
17. Ho YL, Hsu TP, Chen CP, Lee CY, Lin YH, Hsu RB et al. Improved cost-effectiveness for management of chronic heart failure by combined home-based intervention with clinical nursing specialists. J Formos Med Assoc 2007;106:313-9.
18. Dieplinger B, Gegenhuber A, Poelz W, Haltmayer M, Mueller T. Prognostic value of increased adiponectin plasma concentrations in patients with acute destabilized heart failure. Clin Biochem 2009;42:1190-3.
19. Efstathiou SP, Tsiakou AG, Tsioulos DI, Panagiotou TN, Pefanis AV, Achimastos AD et al. Prognostic significance of plasma resistin levels in patients with atherothrombotic ischemic stroke. Clin Chim Acta 2007;378:78-85.
20. Koch A, Weiskirchen R, Sanson E, Zimmermann HW, Voigt S, Duckers H et al. Circulating retinol binding protein 4 in critically ill patients before specific treatment: prognostic impact and correlation with organ function, metabolism and inflammation. Crit Care 2010;14:R179.
21. Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldman AM, Francis GS et al. ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure): Developed in Collaboration With the International Society for Heart and Lung Transplantation; Endorsed by the Heart Failure Society of America. Circulation 2001;104:2996-3007.
22. Lin YH, Lin LY, Wu YW, Chien KL, Lee CM, Hsu RB et al. The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients. Clin Chim Acta 2009;409:96-9.
23. Pecini R, Moller DV, Torp-Pedersen C, Hassager C, Kober L. Heart failure etiology impacts survival of patients with heart failure. Int J Cardiol 2011;149:211-5.
24. Simera I, Moher D, Hoey J, Schulz KF, Altman DG. A catalogue of reporting guidelines for health research. Eur J Clin Invest 2010;40:35-53.
25. Takeishi Y, Niizeki T, Arimoto T, Nozaki N, Hirono O, Nitobe J et al. Serum resistin is associated with high risk in patients with congestive heart failure--a novel link between metabolic signals and heart failure. Circ J 2007;71:460-4.
26. Frankel DS, Vasan RS, D'Agostino RB Sr, Benjamin EJ, Levy D, Wang TJ et al. Resistin, adiponectin, and risk of heart failure the Framingham offspring study. J Am Coll Cardiol 2009;53:754-62.
27. Butler J, Kalogeropoulos A, Georgiopoulou V, de Rekeneire N, Rodondi N, Smith AL et al. Serum resistin concentrations and risk of new onset heart failure in older persons: the health, aging, and body composition (Health ABC) study. Arterioscler Thromb Vasc Biol 2009;29:1144-9.
28. Schulze PC, Biolo A, Gopal D, Shahzad K, Balog J, Fish M et al. Dynamics in insulin resistance and plasma levels of adipokines in patients with acute decompensated and chronic stable heart failure. J Card Fail 2011;17:1004-11.
29. Jamaluddin MS, Weakley SM, Yao Q, Chen C. Resistin: functional roles and therapeutic considerations for cardiovascular disease. Br J Pharmacol 2012;165:622-32.
30. Filkova M, Haluzik M, Gay S, Senolt L. The role of resistin as a regulator of inflammation: implications for various human pathologies. Clin Immunol 2009;133:157-70.
31. Langheim S, Dreas L, Veschini L, Maisano F, Foglieni C, Ferrarello S et al. Increased expression and secretion of resistin in epicardial adipose tissue of patients with acute coronary syndrome. Am J Physiol Heart Circ Physiol 2010;298:H746-53.
32. Chen C, Jiang J, Lu JM, Chai H, Wang X, Lin PH et al. Resistin decreases expression of endothelial nitric oxide synthase through oxidative stress in human coronary artery endothelial cells. Am J Physiol Heart Circ Physiol 2010;299:H193-201.
33. Cho Y, Lee SE, Lee HC, Hur J, Lee S, Youn SW et al. Adipokine resistin is a key player to modulate monocytes, endothelial cells, and smooth muscle cells, leading to progression of atherosclerosis in rabbit carotid artery. J Am Coll Cardiol 2011;57:99-109.
34. Kotani K, Adachi S, Tsuzaki K, Sakane N, Gugliucci A. The association between resistin, high-density lipoprotein cholesterol and carotid atherosclerosis in elderly women with hypertension. Int J Cardiol 2010;141:193-4.
35. Calabro P, Cirillo P, Limongelli G, Maddaloni V, Riegler L, Palmieri R et al. Tissue factor is induced by resistin in human coronary artery endothelial cells by the NF-kB-dependent pathway. J Vasc Res 2011;48:59-66.
36. Baldasseroni S, Mannucci E, Orso F, Di Serio C, Pratesi A, Bartoli N et al. Adiponectin in outpatients with coronary artery disease: independent predictors and relationship with heart failure. Nutr Metab Cardiovasc Dis 2012;22:292-9.
37. Zhang BC, Liu WJ, Che WL, Xu YW. Serum Total adiponectin level and risk of cardiovascular disease in Han Chinese populations: a meta-analysis of 17 case-control studies. Clin Endocrinol (Oxf) 2011; doi:10.1111/j.1365-2265.2011.04260.x.
38. Schram K, Sweeney G. Implications of myocardial matrix remodeling by adipokines in obesity-related heart failure. Trends Cardiovasc Med 2008;18:199-205.
39. Karmazyn M, Purdham DM, Rajapurohitam V, Zeidan A. Signalling mechanisms underlying the metabolic and other effects of adipokines on the heart. Cardiovasc Res 2008;79:279-86.
40. Smith CC, Mocanu MM, Davidson SM, Wynne AM, Simpkin JC, Yellon DM. Leptin, the obesity-associated hormone, exhibits direct cardioprotective effects. Br J Pharmacol 2006;149:5-13.
41. Khalili P, Flyvbjerg A, Frystyk J, Lundin F, Jendle J, Engstrom G et al. Total adiponectin does not predict cardiovascular events in middle-aged men in a prospective, long-term follow-up study. Diabetes Metab 2010;36:137-43.
42. Ibanez J, Izquierdo M, Martinez-Labari C, Ortega F, Grijalba A, Forga L et al. Resistance training improves cardiovascular risk factors in obese women despite a significative decrease in serum adiponectin levels. Obesity (Silver Spring) 2010;18:535-41.
43. McManus DD, Lyass A, Ingelsson E, Massaro JM, Meigs JB, Aragam J et al. Relations of circulating resistin and adiponectin and cardiac structure and function: the framingham offspring study. Obesity 2011; doi:10.1038/oby.2011.32.
44. Rienstra M, Sun JX, Lubitz SA, Frankel DS, Vasan RS, Levy D et al. Plasma resistin, adiponectin, and risk of incident atrial fibrillation: the Framingham Offspring Study. Am Heart J 2012;163:119-24.e1.
45. Krecki R, Krzeminska-Pakula M, Peruga JZ, Szczesniak P, Lipiec P, Wierzbowska-Drabik K et al. Elevated resistin opposed to adiponectin or angiogenin plasma levels as a strong, independent predictive factor for the occurrence of major adverse cardiac and cerebrovascular events in patients with stable multivessel coronary artery disease over 1-year follow-up. Med Sci Monit 2011;17:CR26-32.
46. Ku IA, Farzaneh-Far R, Vittinghoff E, Zhang MH, Na B, Whooley MA. Association of low leptin with cardiovascular events and mortality in patients with stable coronary artery disease: the Heart and Soul Study. Atherosclerosis 2011;217:503-8.
47. Straburzynska-Migaj E, Gwizdala A, Siniawski A, Ochotny R, Grajek S. Leptin and inflammation in patients with chronic heart failure. Kardiol Pol 2010;68:1243-7.
48. Asferg C, Mogelvang R, Flyvbjerg A, Frystyk J, Jensen JS, Marott JL et al. Leptin, not adiponectin, predicts hypertension in the Copenhagen City Heart Study. Am J Hypertens 2010;23:327-33.
49. Hasan-Ali H, Abd El-Mottaleb NA, Hamed HB, Abd-Elsayed A. Serum adiponectin and leptin as predictors of the presence and degree of coronary atherosclerosis. Coron Artery Dis 2011;22:264-9.
50. Wang P, Vanhoutte PM, Miao CY. Visfatin and cardio-cerebro-vascular disease. J Cardiovasc Pharmacol 2012;59:1-9.
51. Al-Daghri NM, Al-Attas OS, Alokail M, Draz HM, Bamakhramah A, Sabico S. Retinol binding protein-4 is associated with TNF-alpha and not insulin resistance in subjects with type 2 diabetes mellitus and coronary heart disease. Dis Markers 2009;26:135-40.
52. Horwich TB, Fonarow GC, Hamilton MA, MacLellan WR, Woo MA, Tillisch JH. The relationship between obesity and mortality in patients with heart failure. J Am Coll Cardiol 2001;38:789-95.
53. Lavie CJ, Osman AF, Milani RV, Mehra MR. Body composition and prognosis in chronic systolic heart failure: the obesity paradox. Am J Cardiol 2003;91:891-4.
54. Field AE, Coakley EH, Must A, Spadano JL, Laird N, Dietz WH et al. Impact of overweight on the risk of developing common chronic diseases during a 10-year period. Arch Intern Med 2001;161:1581-6.
55. Rea TD, Heckbert SR, Kaplan RC, Psaty BM, Smith NL, Lemaitre RN et al. Body mass index and the risk of recurrent coronary events following acute myocardial infarction. Am J Cardiol 2001;88:467-72.
56. Widlansky ME, Sesso HD, Rexrode KM, Manson JE, Gaziano JM. Body mass index and total and cardiovascular mortality in men with a history of cardiovascular disease. Arch Intern Med 2004;164:2326-32.
57. Clark AL, Chyu J, Horwich TB. The obesity paradox in men versus women with systolic heart failure. Am J Cardiol 2012; doi:10.1016/j.amjcard.2012.02.050.